S100A8 and rheumatoid arthritis: Owing to the considerable decrease in the serum MRP8/14 level in RA patients following treatment, this measurement has been established as a powerful predictor of biotherapy response in patients with RA at baseline and could be used to assess response to treatment across diverse mechanisms of action (including adalimumab, IFX, and rituximab) (45).